Bruk av botulinumtoksin A til barn med cerebral parese

Raftemo, Anne Elisabeth Ross; Mahendran, Arani; Hollung, Sandra Julsen; Jahnsen, Reidun; Lydersen, Stian; Vik, Torstein; Andersen, Guro L.

doi:10.4045/tidsskr.18.0554

Cited by 7 publications

(6 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In line with previous studies, we linked the incidence of adverse events with the severity of motor dysfunction 13,31 . Clearly, caution and careful decision‐making are recommended for children in GMFCS levels IV or V when they are treated with Onabotulinumtoxin‐A or Lanbotulinumtoxin‐A.…”

Section: Discussionsupporting

confidence: 69%

“…In line with previous studies, we linked the incidence of adverse events with the severity of motor dysfunction. 13,31 Clearly, caution and careful decision-making are recommended for children in GMFCS levels IV or F I G U R E 1 Total incidence of adverse events after botulinum neurotoxin A injections at each Gross Motor Function Classification System (GMFCS) level.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Adverse events after different forms of botulinum neurotoxin A injections in children with cerebral palsy: An 8‐year retrospective study

Hé

Tang

et al. 2022

Develop Med Child Neuro

View full text Add to dashboard Cite

Cerebral palsy (CP) refers to a group of disorders that can disturb muscle tone, movement, balance, and posture. 1 With complicated aetiology, CP is the most common motor disability of childhood. 2 Spasticity is one of the dominant clinical symptoms of CP, which can contribute to limitations in functional activity, physical fitness, and social participation of children with CP to varying degrees. 3 The latest evidence suggests that botulinum neurotoxin A (BoNT-A) is an optimal way to reduce spasticity in this group by inhibiting acetylcholine release from the neuromuscular junction. 4,5 The decrease of spasticity can help produce opportunities to improve motor function and posture, reduce pain related to spasticity, and ameliorate symptom management. [6][7][8]

show abstract

Section: Discussionsupporting

confidence: 69%

Section: Discussionmentioning

confidence: 99%

Adverse events after different forms of botulinum neurotoxin A injections in children with cerebral palsy: An 8‐year retrospective study

Hé

Tang

et al. 2022

Develop Med Child Neuro

View full text Add to dashboard Cite

show abstract

“…In addition to the quality indicators, NorCP also has reported on wide variations in the use and dosage of Botulinum toxin A for reduction in spasticity in Norway, (55) as well as the use of Botulinum toxin A, selective dorsal rhizotomy and intrathecal baclofen therapies in northern Europe (56).…”

Section: Number Of New Children With Hip Dislocationmentioning

confidence: 99%

The impact of longitudinal surveillance of individuals with cerebral palsy in Norway; a 20-year quality registry and follow-up program perspective

Hollung,

Jahnsen,

Klevberg

et al. 2023

Nor J Epidemiol

View full text Add to dashboard Cite

The Norwegian Quality and Surveillance Registry for Cerebral Palsy (NorCP) has systematically collecteddata on individuals with cerebral palsy (CP) and been a driver of knowledge dissemination for over 20 years.NorCP data have increased the competence of health professionals in both the municipal and specialisthealthcare services through publication of multiple scientific articles ranging from risk factors for CP tolifelong interventions, quality improvement projects, and training services. This has led to a streamlinedprocess in the diagnosis and follow-up of children and youths with CP in Norway to ensure that they receive"the right treatment at the right time," regardless of where they live using evidence-based interventions basedon needs that are revealed in the registrations.NORSK SAMMENDRAGNorsk kvalitets- og oppfølgingsregister for cerebral parese (NorCP) har systematisk samlet inn data ompersoner med cerebral parese og vært en pådriver for kunnskapsformidling i over 20 år. NorCP data har øktkompetansen til helsepersonell i både kommune- og spesialisthelsetjenesten gjennom publisering av flerevitenskapelige artikler om risikofaktorer for CP til livslange intervensjoner, kvalitetsforbedringsprosjektersamt kurs og kompetansetjenester. Dette har ført til økt kvalitet på diagnostisering og oppfølging av barn ogunge med CP i Norge, som sikrer at de får «riktig behandling til rett tid», uansett hvor de bor i landet medbruk av evidensbaserte intervensjoner basert på behov som avdekkes ved registreringene.

show abstract

“…There were large differences, ranging from seven to 20%, in proportions of children treated with BTX-A, with the highest number treated in Sweden and Norway. However, there are also large regional differences regarding use of BTX-A treatment reported from Norway and Sweden [24,25]. Follow-up programs for CP have existed the longest in Sweden and Norway, and the continuous monitoring of muscle tone means that indications for BTX-A treatment are recognized more regularly, and thus it was used more often.…”

Section: Btx-amentioning

confidence: 99%

Treatment of spasticity in children and adolescents with cerebral palsy in Northern Europe: a CP-North registry study

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background Spasticity is present in more than 80% of the population with cerebral palsy (CP). The aim of this study was to describe and compare the use of three spasticity reducing methods; Botulinum toxin-A therapy (BTX-A), Selective dorsal rhizotomy (SDR) and Intrathecal baclofen therapy (ITB) among children and adolescents with CP in six northern European countries. Methods This registry-based study included population-based data in children and adolescents with CP born 2002 to 2017 and recorded in the follow-up programs for CP in Sweden, Norway, Denmark, Iceland and Scotland, and a defined cohort in Finland. Results A total of 8,817 individuals were included. The proportion of individuals treated with SDR and ITB was significantly different between the countries. SDR treatment ranged from 0% ( Finland and Iceland) to 3.4% (Scotland) and ITB treatment from 2.2% (Sweden) to 3.7% (Denmark and Scotland). BTX-A treatment in the lower extremities reported 2017–2018 ranged from 8.6% in Denmark to 20% in Norway (p < 0.01). Mean age for undergoing SDR ranged from 4.5 years in Norway to 7.3 years in Denmark (p < 0.01). Mean age at ITB surgery ranged from 6.3 years in Norway to 10.1 years in Finland (p < 0.01). Mean age for BTX-A treatment ranged from 7.1 years in Denmark to 10.3 years in Iceland (p < 0.01). Treatment with SDR was most common in Gross Motor Function Classification System (GMFCS) level III, ITB in level V, and BTX-A in level I. The most common muscle treated with BTX-A was the calf muscle, with the highest proportion in GMFCS level I. BTX-A treatment of hamstring and hip muscles was most common in GMFCS levels IV-V in all countries. Conclusion There were statistically significant differences between countries regarding the proportion of children and adolescents with CP treated with the three spasticity reducing methods, mean age for treatment and treatment related to GMFCS level. This is likely due to differences in the availability of these treatment methods and/or differences in preferences of treatment methods among professionals and possibly patients across countries.

show abstract

Bruk av botulinumtoksin A til barn med cerebral parese

Cited by 7 publications

References 10 publications

Adverse events after different forms of botulinum neurotoxin A injections in children with cerebral palsy: An 8‐year retrospective study

Adverse events after different forms of botulinum neurotoxin A injections in children with cerebral palsy: An 8‐year retrospective study

The impact of longitudinal surveillance of individuals with cerebral palsy in Norway; a 20-year quality registry and follow-up program perspective

Treatment of spasticity in children and adolescents with cerebral palsy in Northern Europe: a CP-North registry study

Contact Info

Product

Resources

About